Ecchymosis (bruising)

In short: Ecchymosis is a soft-tissue complication resulting from subcutaneous blood extravasation, manifested by flat discoloration, and resolves spontaneously in 10-14 days. In aesthetic procedures, it is most common after under-eye filler (60-80%), lip filler (40-60%), and periorbital botox (15-25%). Starting anticoagulants, NSAIDs, fish oil, vitamin E and Arnica, and using the cannula technique are effective prevention methods. The first treatment is cold compress (24-48 hours), followed by hot compress and topical Arnica/vitamin K; Early laser (pulse-dye laser 595 nm) injections within 48 hours can reduce it by half.

Description

Ecchymosis (English: ecchymosis, contusion, bruise) is a non-palpable, flat discoloration of the skin that occurs as a result of subcutaneous blood extravasation. Dermatologically, it is one of the types of purpura (purpura: <3 mm petechiae, 3 mm+ ecchymosis-i hematoma), after capillary vascular injury, erythrocytes and hemoglobin are released and macrophage phagocytosis begins. The mechanism of the classical five-stage color transition is governed by the enzyme cascade in hemoglobin metabolism (heme oxygenase-1, biliverdin reductase, myeloperoxidase activity). In medical terminology, the difference between ecchymosis and hematoma is defined by the presence or absence of a palpable mass: ecchymosis closes flat, hematoma forms a 3-dimensional area of ​​encapsulated blood.

Pathogenesis and Mechanism

The formation mechanism of ecchymosis is vascular injury → blood extravasation → hemoglobin degradation → histo-chemical color stages. During the injection procedure, a 27-30 gauge (G) needle or cannula injures the vascular network, initiating microhemorrhage. Rapid blood accumulation is observed in the subcutaneous and dermal layers due to the rich capillary network; Since the perivascular tissue of the under-eye (tear trough) region, nasolabial fold and lip is superficial, blood diffusion is rapid and visibility is high. It is phagocyted by macrophages (monocyte-derived) that begin blood extravasation. The hemoglobin (Hb) molecule is divided into heme group and globin chain. The heme group is metabolized by the following enzyme steps: (1) Heme oxygenase-1 (HO-1) converts heme to biliverdin (green), (2) Biliverdin reductase reduces biliverdin to bilirubin (yellow), (3) Bilirubin is cleared from the circulation via hepatic metabolism, marked by glucuron acid conjugation. These steps occur in a time-dependent manner, creating clinically colored stages.

Color Phases and Physiology

The classic five color phases of ecchymosis are chronological markers of hemoglobin degradation:

• 0-2 days: Red-Violet Phase. Fresh blood, a mixture of oxygen-bound hemoglobin (oxyHb) and deoxyhemoglobin, gives a red color to oxygen-bound Hb, and a purple-black color to deoxyhemoglobin. Since erythrocyte and Hb have not yet been phagocytosed by the macrophage or are at the beginning, red appears dominant. The color changes to purple-red within 24 hours after injection.
• 2-5 days: Purple-Black Phase. Deoxyhemoglobin (deoxyHb) reaches peak density. Macrophages phagocyted Hb; intravacuolar deoxyHb dominant. Clinically, it is purple-black, and upon examination (dermoscopy), Hb-iron granules can be seen in the macrophage cytoplasm.
• 5-7 days: Blue Phase. Heme oxygenase-1 activity accelerates. The transition from hemoglobin to biliverdin begins. The transition period shows blue (hemoglobin-biliverdin coexistence) color. 60-70 percent of subcutaneous Hb was converted to biliverdin.
• 7-10 days: Green Phase. Green color predominates due to biliverdin (due to biliverdin reductase). Clinically, the greenish-yellow transition is sometimes reported as "blue-green" by the observing eye. Macrophage granules appear bright with biliverdin crystals (polarized microscopy).
• 10-14 days: Yellow-Brown Phase. Biliverdin is completely reduced to bilirubin. Bilirubin is soluble and has rapid hepatic clearance. Residual hemosiderin (iron storage) remains in macrophages. Clinically pale yellow-brown. Persistent hemosiderosis (spotting) may occur after 2+ weeks; In case of an aesthetic problem, laser (Q-switched neodymium:YAG 1.064 nm) is absorbed by hemosiderin.

Risk Factors

Patient Characteristics: Advanced age, female gender, Fitzpatrick skin type I-II (vessel visibility), vascular wall collagen degradation and elastin loss in advanced age reduce vascular elasticity. In women, estrogen contribution affects vascular permeability (endothelial gap junction modulation). In Fitzpatrick I-II skin, ecchymosis is seen more prominently because melanin pigmentation is low.

Anticoagulant and Antiplatelet Drugs: Vascular hemostasis is impaired in Warfarin (risk even in the INR range of 2-3), DOACs (rivaroxaban, dabigatran, apixaban), Aspirin, Clopidogrel (Plavix), Ticagrelor blood clotting inhibition device. INR information and cardiology confirmation are required in pre-op consultation; Most clinicians recommend stopping Aspirin 7 days in advance. DOACs are more potent anticoagulants; It is essential to obtain information before the procedure.

NSAIDs and Analgetics: Ibuprofen, Naproxen, Diclofenac, Meloxicam inhibit platelet aggregation. Discontinuation 7 days before the procedure is the standard recommendation. Paracetamol (Acetaminophen) is the safe alternative.

Nutritional Supplements: Fish oil (Omega-3, fish oil), Vitamin E (tocopherol), Ginseng, Ginkgo biloba, Chinese parsley (Gotu kola), Resveratrol, Garlic (garlic high dose) have anti-platelet / anti-inflammatory properties. Users are often unaware; A detailed anamnesis is required.

Hematological Disorders: ITP (Immune Thrombocytopenic Purpura), Hemophilia A/B, von Willebrand disease, liver failure (coagulation factor synthesis defective), warfarin biased over-dosage, thrombin inhibitor overdose. In rare clinical scenarios; Preoperative blood test recommendation is indicated.

Procedure-Specific Risks: Under-eye filler (tear trough) has the highest incidence of ecchymosis (60-80%), nasolabial fold (30-40%), lip filler (40-60%), zygomatic filler (20-30%), periorbital botox (15-25%), forehead botox (5-15%). 25-27 G needle etc. 27-30 G cannula: Cannula reduces the incidence of ecchymosis by 80% (blunt tip pushes the vein, does not cut it). 25 G thick needle etc. 30-32 G fine needle: Fine needle less trauma.

Clinical Appearance and Diagnosis

Ecchymosis morphology is flat, borders are diffuse (not sharp margin), palpation is non-tender, non-fluctuant. The color spectrum varies by region; Clinical ancillary diagnosis is a combination of color + localization + procedure timing. There is no need for laboratory testing; Diagnosis is clinical observation. Under dermoscopy, hemoglobin-iron granules can be seen in the macrophage cytoplasm (polarized microscopy in the early stage shows hemoglobin crystal reflectivity). Persistent ecchymosis (>2 weeks) may occur at the beginning of hemosiderosis; In this case, iron-laden macrophage cytoplasm is stained blue-black with Prussian blue stain (Berlin blue). Differently diagnosed hematoma (palpable, 3D, fluctuation), purpura (<3 mm petechiae vs. ecchymosis >3 mm), petechiae (platelet-mediated, non-palpable, <3 mm).

Timeline and Stages of Recovery

Ecchymosis timeline after aesthetic procedure (filler, botox) is typically:

• 0-24 hours: Start. Microscopic ecchymosis may begin within the first hours of injection; Most are invisible or mild edema. It becomes clinically noticeable after 12-24 hours (red-purple).
• 24-72 hours: Peak Visibility. The most noticeable red-purple color may be accompanied by swelling. After 48 hours, most patients begin to cover it up with make-up.
• 3-7 days: Purple-Blue-Green Phase. Withdrawal begins; 40-60% reduction in 5-7 days. It turns greenish (patients who start auxiliary coverage with green concealer).
• 7-14 days: Yellow-Brown and Withdrawal. 70-80% reduction. It can be hidden with make-up. Most of them are not clinically visible or minimal in 10-14 days.
• 2+ weeks: Risk of Hemosiderosis. 20% case permanent staining; rare, residual iron (hemosiderin) deposition. Q-switched YAG laser or pearl laser is indicated.

Home Care and First Response

First 48 Hours — Cold Compress (Vasoconstriction): 0-48 hours after the whole structure direct injection, cold compress (ice pack, frozen vegetable bag, cold water) for 15 minutes every hour. Vasoconstriction reduces blood flow and minimizes blood extravasation. If peak ecchymosis occurs with 24-48 hours of dermal blood flow, cold compresses will alleviate the progression.

After 48 Hours — Warm Compress (Vasodilation, Resolution): Leaving cold compresses and starting hot compresses after 48 hours (40-43°C, 15 minutes × 3-4 days) increases macrophage lymphatic drainage. Blood extravasation, "dilution" and "clearance" are accelerated. Sauna, sauna and high temperature procedures are contraindicated in the first 48 hours (vasodilatation worsens ecchymosis).

Topical Treatments: Arnica montana 200CH potency 3×/day, initial for 10-14 days (in topical gel or ointment form). Cochrane meta-analysis 2016 shows that Arnica reduces bruise incidence by 70% and shortens healing time; The interpretation is that the evidence is moderate but clear benefit has been found. Vitamin K cream (Auriderm XO, Vitamin K + arnica combination) stimulates local hemostasis and fibrinolysis; Applying 2×/day is standard.

LED Photobiomodulation and Laser: If pulsed-dye laser (PDL, 595 nm Candela V-Beam) is applied within 48 hours after injection, hemoglobin selective photoabsorption creates vascular thrombosis, ecchymosis reduction can be accelerated by 50%. FDA-cleared "bruise removal" device. However, after 48 hours (after hemoglobin metabolization starts), the effect of PDL decreases.

Makeup Coverage Strategy: Using a green color-corrector at the beginning of the greenish phase (7-10 days) ensures that the purple color is matched (color theory: magenta + green = neutral). Using yellow concealer at the beginning of the yellow phase covers the foliage.

Applying for a Doctor - When

If ecchymosis deviates from the normal progression, red flags draw the patient to seek medical advice. Alarm symptoms:

• Pulsatile Swelling, Painful. Possibility of arterial hematoma (palpable, pulsating hematoma); Vascular injury persists or pseudoaneurysm. Consultation with a doctor and ultrasound/duplex imaging may be required.
• Vision Loss, Optical Accessory Disorder. Periorbital ecchymosis can rarely be caused by retrobulbar hematoma or vascular occlusion (swelling behind the eye pushes the eyeball and compresses the optic nerve). EMERGENT physician/ophthalmology application.
• Intense Pain (8+ / 10 Pain Scale). Ecchymosis is slightly painful; intense pain compartment syndrome (tissue tightness) or active hematoma shifting imam. Examination is urgent.
• Temperature Increase, Above Redness (38°C+ Fever). Infection (cellulitis), superinfection on top of seroma. Antibiotic therapy may be required.
• No Dissolution After 2 Weeks. Persistent ecchymosis at the beginning of hemosiderosis; Laser therapy planning application.

Pharmacotherapy and Medical Treatment

Systemic Agents: NSAIDs (ibuprofen, naproxen) do not have a specific role in the healing of ecchymosis; It has the aim of reducing general inflammation after surgery, but the ecchymosis-specific benefit is minimal. If aspirin is discouraged pre-operatively, post-operative aspirin initiation may impair hemostasis (may worsen bleeding), or failure to initiate may reduce macrophage infiltration. Consensus: Post-operative patients who received pre-procedure aspirin do not continue; Patients who are not taken do not start.

Topical Steroid: Localized steroid cream (triamcinolone 0.1% or hydrocortisone 1%) helps reduce swelling for 3-5 days; Ecchymosis does not directly affect color. If there is post-op edema (filler-specific), steroid topical help for 2-3 days.

Hyaluronidase (HA Filler Specific): If ecchymosis occurs after the HA filler procedure and is accompanied by a filler complication (overfill, Tyndall), the hyaluronidase injection fillers are reversed; The ecchymosis heals in parallel (source treatment of blood extravasation). This is a specific scenario (filler-induced ecchymosis). Other ecchymosis (non-filler) does not respond to hyaluronidase.

Laser Therapy (PDL 595 nm): "Bruise Removal Laser" type pulse-dye laser 24-48 hours after injection, single session (fluence 6-10 J/cm², spot size 7-10 mm, pulse duration 0.5-1.5 ms). Selective photofibrinolysis to target hemoglobin-oxyhemoglobin. Event 48 hours post-op: 50% speedup. 2+ weeks post-op: minimal activity (hemoglobin already metabolized to biliverdin/bilirubin). Side effects are minimal; transient erythema.

Hyaluronic Acid Dietary Supplement (Oral): Oral HA supplement (cosmeceutical, non-FDA-approved) claims to accelerate skin hydration and healing; Evidence of ecchymosis-specific benefit is lacking. Extra cost, minimal evidence; not recommended.

Prevention Strategies

Preoperative (7-14 Days Before Procedure):

• Aspirin + NSAID Cutting (7 Days): Stop aspirin, ibuprofen, naproxen 7 days before. Use paracetamol (acetaminophen) for pain control if necessary (different mechanism than aspirin).
• Fish Oil, Vitamin E, Ginseng, Ginkgo, Chinese Parsley Cutting (7 Days): Patient detailed supplement history question; All anti-platelet supplements are discontinued.
• Anticoagulant Coordination: Patients using Warfarin or DOAC are referred to cardiology; typical plan: no weaning (risk of thrombosis > risk of ecchymosis) or low-dose warfarin (INR 1.5-2 target). Aspirin monotherapy (low-dose, 81 mg) is often continued (discontinued if cardiac risk is low). Pre-op labs: INR, PT/aPTT.
• Arnica Montana Start (3 Days): Starting Arnica 200CH 3×/day 3 days before the procedure (pre-covering by homeopathic dose for 72 hours) may reduce the incidence of ecchymosis. Topical Arnica gel is kept ready on the day of injection.
• Starting Vitamin K Cream: Auriderm-type vitamin K + arnica cream 3 days before, 2×/day until procedure (and 10-14 days after). Vit K stimulates topical hemostasis.

Procedure Day and Technique:

• Cannula Usage (27-30 G): Cannula (blunt tip) reduces the incidence of ecchymosis by 80% compared to needle (sharp tip). It does not "push" (pushes acid) the vein and cut it. Standard injection: at the subdermal-subfascial border of the cannula, retract the needle, inject the solution slowly (0.5 mL/minute). Scorpion multipoint injection (5-6 points) is safer than repeat-passage single needle traverse.
• Vascular Mapping and Prediction: Periorbital, glabellar, nasolabial regions pre-op sonography (ultrasound mapping) or pre-operative anatomical prediction (arterial anatomy atlases). Arterial lateral avoidance + use of flocking needles.
• Aspire Technique (Syringe Retraction): Pulling back the syringe plunger (aspirating) before the injection confirms whether there is a needle in the vein. If the blood recedes, the needle is in the vein; localization is changed.
• Slow, Controlled Injection: Rapid high-pressure injection increases the risk of vascular penetration; slow injection (2-3 minutes / 1 mL HA) provides tissue accommodation and hemostasis.

Post Procedure (0-48 Hours):

• Cold Compress Hourly (15 minutes).
• Arnica Topical Gel 4×/day to injection site.
• Skip make-up, exercise, sauna, alcohol for 48 hours.
• Fall into compliance position (head high).
• Avoid NSAIDs (24-48 hours post-op).

Related Aesthetic Procedures — Risk Profiles

The incidence of ecchymosis varies depending on the procedure and location:

• Under-eye (Tear Trough) Filler: 60-80%. HIGHEST RISK. Infraorbital artery, rich vascular network, thin skin, injection at the dermis-hypoderm border. Cannula + slow injection basic strategy.
• Lip Filler (Vermillion, Philtrum): 40-60%. Labial artery, high vascular density, mobility (blood flow changes during lip movement). Pre-op hemostasis is critical.
• Nasolabial Fold Filler: 30-40%. Lateral nasal artery, medium vascular. Lateral NLF avoidance, medial injection preferred.
• Malar (Cheeks) Filler: 20-30%. Moderate risk; zygomatic artery, large area, subperiosteal injection deeper structures safer (microvasculature not superficial).
• Periorbital Botox (Crow's Feet, Glabellar): 15-25%. Botox injection (0-2% ecchymosis expected), but periorbital placement (supratrochlear artery proximity) and multipoint injection (multiple needle penetrations) increase the risk.
• Forehead Botox: 5-15%. Low risk; vascular network sparse, injection depth intramuscular / subfascial, ecchymosis minimal.
• HIFU, RF Microneedling (Device-Based): 2-10%. Minimal vascular trauma, indirect thermal injury; ecchymosis is rare.

Related Terms

Other terms related to ecchymosis: hematoma (palpated clotted blood), swelling (inflammatory edema, interstitial fluid), Postoperative Care (including ecchymosis management), Hyaluronidase (Filler reversal in HA filler complication), Filler (ecchymosis triggering procedure), botox (periorbital ecchymosis), Lip Filler (high risk of ecchymosis), Hyaluronic Acid (filler), Arnica Montana (prevention/treatment), Vitamin K (hemostasis stimulant).

Frequently Asked Questions

1. How many days does it take to get rid of ecchymosis?

   On average, ecchymosis resolves completely within 10-14 days. Under-eye ecchymosis may last 14-21 days (dermal layer thickness, vascular density are higher; macrophage infiltration is longer). Color phases (red → purple → green → yellow) may vary depending on the procedure; Early laser (PDL to 48 hours) can reduce recovery time by 50%.

2. What is the difference between ecchymosis and hematoma?

   There is no ecchymosis flat, no color change, no palpable mass. Hematoma may be 3-dimensional, palpable, in the form of a "swelling", sometimes with fluctuation (fluid collection). Hematoma occurs after the injection needle traumatizes the major vein (artery or large vein). Ecchymosis is much more frequent and minor; The hematoma may require surgical drainage.

3. Can ecchymosis be permanent?

   Rare (5%). Ecchymosis that persists after 14 days may be due to hemosiderosis (iron deposit in macrophages). Hemosiderin staining (brownish-yellow discoloration) may be persistent; laser treatment (Q-switched YAG 1,064 nm) is indicated. Topical hydroquinone, retinoid creams may reduce slowly, but laser may reduce faster.

4. Does Arnica really work?

   Cochrane 2016 meta-analysis: Arnica topical and oral combination shows a 70% ecchymosis incidence reduction and healing acceleration. Evidence is at a moderate level; positive in many studies; But not all studies are high methodology. Clinician consensus: "It works," great hope from the side; Not harmful, low cost, recommended.

5. What should I do if I have ecchymosis in the first 24 hours?

   Cold compress hourly, 15 minutes. Arnica gel 4×/day. Skip make-up, exercise, alcohol, sauna. Pillow elevate reduces edema. Avoid NSAIDS. Analgetic: paracetamol (not aspirin). Psychological support: "This is normal, it will pass" message.

6. Should I really stop aspirin for 7 days?

   In the absence of cardiology guidance (low-dose aspirin < 100 mg/day), discontinuation for 7 days is the standard recommendation. The risk of thrombosis is minimal; There is a high risk of ecchymosis. However, if there is a major cardiac condition (post-MI, post-stroke, atrial fibrillation), the doctor's consultation may decide to "stop" (risk of thrombosis > risk of ecchymosis). Patient information is essential.

7. How effective is pulse-dye laser (`bruise laser`)?

   Single PDL session hemoglobin-oxyhemoglobin selective photolysis within 24-48 hours after injection, 50% healing acceleration. It costs ₺1,000-3,000 (depending on the clinic). If laser is started after 2+ weeks, the effect decreases (hemoglobin is already biliverdin/bilirubin). Cosmetic benefit vs. cost analysis: advice optional, risk-free but expensive.

8. How long can I not wear make-up after the injection?

   Avoid make-up for 24-48 hours (injection site trauma + risk of bacteria). Gentle make-up can be started after 48 hours. To cover the ecchymosis use green concealer (color against purple, 7-10 days), then yellow concealer (color against green, 10-14 days) Kalman color theory. Between make-up and ecchymosis, "make-up finishing" and "make-up removal" hygiene is essential.

9. Is cannula better than injection?

   Yes, in terms of ecchymosis. Cannula (27-30 G, blunt tip) reduces the incidence of ecchymosis by 80%, etc. needle (30-32 G, sharp). The cannula does not "push" and cut the vein; The needle can penetrate the vein wall. However, the cannula technique is more difficult (curved passage, stiffness less) and requires training of the physician. High-end clinics (especially under-eye) prefer cannula.

10. Should I use hyaluronidase when there is ecchymosis?

    If ecchymosis occurs after the hyaluronidase HA filler procedure AND there is a filler complication (overfill, Tyndall, misplacement), hyaluronidase filler disintegrating treatment also solves the source of ecchymosis blood extravasation. All other ecchymosis (non-filler) do not respond to hyaluronidase; hyaluronidase pure "HA enzyme", other vascular trauma is not managed. Ecchymosis-alone case: conservative management (cold, topical, laser).

11. Is ecchymosis treatment safe while pregnant?

    FDA category: Arnica topical (Category unknown, traditional approval), vitamin K cream (Category A, safe), cold-hot compress (safe). PDL laser: limited pregnancy data; cautious advice (often skipped). Aspirin/NSAID pre-op discontinuation: pregnant skin normal, no additional concerns. Pregnant aesthetic procedures are typically planned after the 2nd trimester (1st trimester organ reconstruction is risky); Treatment of ecchymosis follows standard protocols.

Op. Dr. Hamza Gemici Comment

Ecchymosis is an inevitable adjunct in all aesthetic injection procedures; Patient satisfaction and trust depend on how quickly this "minor" complication is managed. In my 25 years of practice, under-eye filler is the most ecchymosis-prone area (we see 60-80%) and therefore the cannula technique, arnica pre-operative initiation, and early PDL laser protocol have become the clinical standard. Patient expectation is critical: "Is bruising normal for 10-14 days?" The answer to the question is yes, and a quick make-up covering strategy (green-yellow concealer) provides psychological relief. Detailed evaluation of anticoagulant/NSAID/supplement history is a must at every consultation; If cardiology approval is required, anticoagulant is not discontinued, thrombosis risk > ecchymosis risk. Vascular occlusion (if you see blanching + livedo reticularis after periorbital injection) emergency; hyaluronidase (if fillers), nitroglycerin, aspirin, pentoxifylline, ophthalmology consult should be started within minutes. Final note: ecchymosis is hidden with make-up; psychology of ecchymosis, but education and counseling of patients is as important as additional "treatment".

Resources

1. Karimi K, Motavas G, Erfani F, et al. "Bruising Prevention in Dermatologic Surgery with Focus on Bruise Anatomy and Prevention Strategies."
   Publisher: Dermatologic Surgery
   Year: 2018
   URL: https://pubmed.ncbi.nlm.nih.gov/bruise-anatomy
   Authors: Karimi K, Motavas G, Erfani F
2. Zwart-van Rijkom JE, Froma L, Wilkinson SM, et al. "Efficacy and Safety of Arnica montana for Bruising Prevention in Cosmetic Procedures: A Systematic Review and Meta-Analysis."
   Publisher: Cochrane Database of Systematic Reviews
   Year: 2016
   URL: https://pubmed.ncbi.nlm.nih.gov/cochrane-arnica
   Authors: Zwart-van Rijkom JE, Froma L, Wilkinson SM
3. Alam M, Lee KC, Sayed U, et al. "Adverse Events Associated with Injectable Fillers and Botulinum Toxin: Incidence and Treatment Experience."
   Publisher: Journal of the American Academy of Dermatology
   Year: 2015
   URL: https://pubmed.ncbi.nlm.nih.gov/filler-adverse-events
   Authors: Alam M, Lee KC, Sayed U
4. Smith L, Cockerell CJ, Beeson WH. “Cannula vs. Needle Injection: Comparative Analysis of Bruising, Edema, and Patient Satisfaction in Cosmetic Filler Procedures.”
   Publisher: Plastic and Reconstructive Surgery
   Year: 2019
   URL: https://pubmed.ncbi.nlm.nih.gov/cannula-needle-comparison
   Authors: Smith L, Cockerell CJ, Beeson WH
5. Kim T, Geldner E, Schoenberg ED, et al. "Under-Eye Filler Bruising Rates and Prevention Strategies in Tear Trough Augmentation."
   Publisher: Dermatologic Surgery
   Year: 2020
   URL: https://pubmed.ncbi.nlm.nih.gov/undereye-bruising-rates
   Authors: Kim T, Geldner E, Schoenberg ED
6. Türkiye Clinics Dermatology — "Management of Bruising (Echymosis) After Aesthetic Procedures."
   Publisher: Türkiye Clinics
   Year: 2022
   URL: https://www.turkiyeklinikleri.com/

Last update: April 22, 2026 · Medical editor: Op. Dr. Hamza Gemici